Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

PURPOSE: To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). PATIENTS AND METHODS: Patients with previously untreated AML or...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Garcia-Manero, Guillermo, Tambaro, Francesco Paolo, Bekele, Nebiyou B., Yang, Hui, Ravandi, Farhad, Jabbour, Elias, Borthakur, Gautam, Kadia, Tapan M., Konopleva, Marina Y., Faderl, Stefan, Cortes, Jorge E., Brandt, Mark, Hu, Yumin, McCue, Deborah, Newsome, Willie Mae, Pierce, Sherry R., de Lima, Marcos, Kantarjian, Hagop M.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2012
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879705/
https://ncbi.nlm.nih.gov/pubmed/22585696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.38.3265
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky